MX354249B - Formas de dosificación farmacéuticas intranasales que comprenden naloxona. - Google Patents

Formas de dosificación farmacéuticas intranasales que comprenden naloxona.

Info

Publication number
MX354249B
MX354249B MX2013013276A MX2013013276A MX354249B MX 354249 B MX354249 B MX 354249B MX 2013013276 A MX2013013276 A MX 2013013276A MX 2013013276 A MX2013013276 A MX 2013013276A MX 354249 B MX354249 B MX 354249B
Authority
MX
Mexico
Prior art keywords
pharmaceutical dosage
naloxone
intranasal pharmaceutical
dosage forms
dosage form
Prior art date
Application number
MX2013013276A
Other languages
English (en)
Other versions
MX2013013276A (es
Inventor
Strang John
Oksche Alexander
Harris Stephen
Smith Kevin
Helene Jeanne Mottier Lucie
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44658496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354249(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2013013276A publication Critical patent/MX2013013276A/es
Publication of MX354249B publication Critical patent/MX354249B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma de dosificación farmacéutica intranasal que comprende una unidad de dosificación que comprende naloxona o una sal de la misma aceptable desde el punto de vista farmacéutico en una cantidad de equivalente a = 0,5 mg de naloxona HCI disuelta en un líquido de aplicación de un volumen de = 250 µl. Además, tal forma de dosificación farmacéutica intranasal para uso en el tratamiento de sobredosis de opiáceos y/o al menos un síntoma de la misma.
MX2013013276A 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona. MX354249B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166076 2011-05-13
PCT/EP2012/058792 WO2012156317A2 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone

Publications (2)

Publication Number Publication Date
MX2013013276A MX2013013276A (es) 2014-08-07
MX354249B true MX354249B (es) 2018-02-20

Family

ID=44658496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013276A MX354249B (es) 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona.

Country Status (36)

Country Link
US (7) US20150018379A1 (es)
EP (2) EP3320893A1 (es)
JP (3) JP6110367B2 (es)
KR (2) KR101873174B1 (es)
CN (2) CN103764119A (es)
AR (1) AR086391A1 (es)
AT (1) AT16553U1 (es)
AU (2) AU2012257785B2 (es)
BR (1) BR112013029126A2 (es)
CA (1) CA2835940C (es)
CO (1) CO6821959A2 (es)
CY (1) CY1120399T1 (es)
DE (1) DE202012013606U1 (es)
DK (2) DK2706982T4 (es)
ES (1) ES2661838T5 (es)
HK (1) HK1255428A1 (es)
HR (1) HRP20180233T1 (es)
HU (1) HUE036465T2 (es)
IL (1) IL229409B (es)
LT (1) LT2706982T (es)
ME (1) ME02958B (es)
MX (1) MX354249B (es)
MY (1) MY194947A (es)
NO (1) NO2706982T3 (es)
PH (1) PH12016501342B1 (es)
PL (1) PL2706982T3 (es)
PT (1) PT2706982T (es)
RS (1) RS57054B1 (es)
RU (2) RU2657441C1 (es)
SG (1) SG194927A1 (es)
SI (1) SI2706982T1 (es)
TR (1) TR201802716T4 (es)
TW (1) TWI486161B (es)
UA (1) UA110974C2 (es)
WO (1) WO2012156317A2 (es)
ZA (1) ZA201308280B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
TWI486161B (zh) * 2011-05-13 2015-06-01 Euro Celtique Sa 含那若松（ｎａｌｏｘｏｎｅ）的鼻內藥物劑型
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
SG10202003562WA (en) * 2014-03-14 2020-05-28 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
US11135155B2 (en) * 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA2954637A1 (en) * 2014-07-09 2016-01-14 Opiant Pharmaceuticals, Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
WO2017011326A1 (en) * 2015-07-10 2017-01-19 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
CA2950687C (en) * 2015-09-17 2023-02-28 Adapt Pharma Limited Nasal drug products and methods of their use
RU2767062C2 (ru) * 2016-06-24 2022-03-16 Опиант Фармасьютикалз, Инк. Составы, устройства и способы для лечения алкогольной зависимости
JP7114570B2 (ja) * 2016-08-17 2022-08-08 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド 液体ナロキソンスプレー
CN114144224A (zh) * 2019-03-26 2022-03-04 保科特纳洛克斯恩公司 药物合成物输送器械和方法
AU2020245535B2 (en) * 2019-03-26 2022-06-30 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
AU2021276611A1 (en) 2020-05-18 2022-12-15 Orexo Ab New pharmaceutical composition for drug delivery
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9908921D0 (en) † 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
PL352556A1 (en) 1999-06-16 2003-08-25 Nastech Pharmaceutical Co Pharmaceutical formulations and methods comprising intranasal morphine
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
DK1642578T3 (da) * 2000-07-31 2013-08-12 Takeda Pharma As Fentanyl salt-sammensætning til nasal administration
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EP1535615A4 (en) 2002-07-11 2010-03-31 Taiho Pharmaceutical Co Ltd COMPOSITION FOR THE NASAL ABSORPTION
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
CN1575795A (zh) * 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
EP1785145A4 (en) 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
ATE416398T1 (de) * 2004-11-09 2008-12-15 Koninkl Philips Electronics Nv Array von räumlichen lichtmodulatoren und verfahren zur herstellung einer räumlichen lichtmodulationsvorrichtung
CA2587792C (en) * 2004-12-23 2010-07-06 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
RU2344822C2 (ru) * 2006-04-05 2009-01-27 Алексей Валентинович Надеждин Способ лечения героиновой наркомании
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
CA2676010C (en) * 2007-01-19 2016-05-17 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
TWI486161B (zh) * 2011-05-13 2015-06-01 Euro Celtique Sa 含那若松（ｎａｌｏｘｏｎｅ）的鼻內藥物劑型
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
SG10202003562WA (en) 2014-03-14 2020-05-28 Opiant Pharmaceuticals Inc Nasal drug products and methods of their use
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray

Also Published As

Publication number Publication date
US20150126540A1 (en) 2015-05-07
EP2706982B2 (en) 2021-03-10
EP2706982B1 (en) 2018-01-03
ZA201308280B (en) 2014-07-30
TWI486161B (zh) 2015-06-01
AR086391A1 (es) 2013-12-11
HRP20180233T1 (hr) 2018-06-01
CN103764119A (zh) 2014-04-30
PH12016501342A1 (en) 2018-06-11
JP2016128453A (ja) 2016-07-14
AU2012257785B2 (en) 2016-04-14
SG194927A1 (en) 2013-12-30
IL229409A0 (en) 2014-01-30
PH12016501342B1 (en) 2018-06-11
ES2661838T3 (es) 2018-04-04
SI2706982T1 (en) 2018-05-31
US20170231904A1 (en) 2017-08-17
KR20140007482A (ko) 2014-01-17
KR101698182B1 (ko) 2017-01-19
RS57054B1 (sr) 2018-05-31
MX2013013276A (es) 2014-08-07
US11806428B2 (en) 2023-11-07
CA2835940C (en) 2020-08-04
US20240082149A1 (en) 2024-03-14
AU2012257785A1 (en) 2013-11-28
CY1120399T1 (el) 2019-07-10
IL229409B (en) 2020-10-29
RU2587051C2 (ru) 2016-06-10
JP2014513683A (ja) 2014-06-05
JP2018150336A (ja) 2018-09-27
US20210338574A1 (en) 2021-11-04
NZ705933A (en) 2016-07-29
CA2835940A1 (en) 2012-11-22
JP6110367B2 (ja) 2017-04-05
US20170304192A1 (en) 2017-10-26
AT16553U1 (de) 2020-01-15
TW201311244A (zh) 2013-03-16
HK1255428A1 (zh) 2019-08-16
PL2706982T3 (pl) 2018-07-31
DK2706982T4 (da) 2021-05-10
DE202012013606U1 (de) 2018-04-18
NO2706982T3 (es) 2018-06-02
LT2706982T (lt) 2018-05-25
WO2012156317A2 (en) 2012-11-22
TR201802716T4 (tr) 2018-03-21
HUE036465T2 (hu) 2018-07-30
US20190374464A1 (en) 2019-12-12
DK2706982T3 (en) 2018-03-12
CO6821959A2 (es) 2013-12-31
AU2016204880B2 (en) 2017-11-23
KR20170010078A (ko) 2017-01-25
BR112013029126A2 (pt) 2017-02-07
EP2706982A2 (en) 2014-03-19
DK201800034U1 (da) 2018-05-25
CN107260672A (zh) 2017-10-20
US11020343B2 (en) 2021-06-01
AU2016204880A1 (en) 2016-07-28
NZ617442A (en) 2015-03-27
KR101873174B1 (ko) 2018-06-29
UA110974C2 (uk) 2016-03-10
PT2706982T (pt) 2018-03-08
RU2013155479A (ru) 2015-06-20
EP3320893A1 (en) 2018-05-16
ES2661838T5 (es) 2021-11-18
ME02958B (me) 2018-07-20
US20150018379A1 (en) 2015-01-15
MY194947A (en) 2022-12-27
RU2657441C1 (ru) 2018-06-13
WO2012156317A3 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
PH12016501342A1 (en) Intranasal pharmaceutical dosage forms comprising naloxone
HK1200741A1 (en) Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
PL2120878T3 (pl) Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
IL222012A (en) Controlled-release dosage forms for high-dose hygroscopic and water-soluble pharmaceuticals
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
EP2406765A4 (en) DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR
WO2013048558A3 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
EP2822561A4 (en) STABLE LIQUID PHARMACEUTICAL COMPOSITION CONTAINING PIROXICAM OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND HYALURONIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND METHOD OF MAKING THE COMPOSITION
MX339552B (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia.
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
MX357556B (es) Composiciones acuosas que comprenden arbekacina.
MD4615C1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
MX2016007370A (es) Agente terapeutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
EA201590732A1 (ru) Диспергируемая таблетка
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Legal Events

Date Code Title Description
FG Grant or registration